Latest Sleep Disorder Treatments News

SomnoMed Limited has reported a return to profitability for the half-year ending December 2025, posting a $792,000 net profit after tax on the back of a 13% revenue increase. Despite the positive turnaround, the company has elected not to pay an interim dividend.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.